Pacritinib Approval Status
FDA Approved: No
Generic name: pacritinib
Company: CTI BioPharma Corp.
Treatment for: Myelofibrosis
Pacritinib is an investigational oral JAK2/FLT3 multikinase inhibitor in development for the treatment of patients with myelofibrosis.
Development Status and FDA Approval Process for pacritinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.